News for Anavex Life Sciences Corp. (AVXL)

NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (”œAnavex” or the ”œCompany”) ( AVXL), a clinical-stage biopharmaceutical company

**media[548363]**

Anavex Life Sciences Corp.'s stock rises 50% as EMA reviews Alzheimer's drug blarcamesine. Click for my updated look at AVXL stock and why I have upgraded it.

Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O NAVXL.OQ - Anavex Life Sciences CorpQ1 2025 Anavex Life Sciences Corp Earnings CallFeb 12, 2025

Anavex Life Sciences Corp. expects feedback from the European Medicines Agency on blarcamesine for Alzheimer's Disease this year. Click for my AVXL stockupdate.

A hotter-than-expected inflation report initially rattled markets on Wednesday morning, but investors found confidence to buy the dip, helping major indexes recover most losses by midday trading in New York.

Anavex Life Sciences Corp. (NASDAQ:AVXL) Q1 2025 Earnings Conference Call February 12, 2025 8:30 AM ETCompany ParticipantsClint Tomlinson - IRChristopher...

Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (”œAnavex” or the ”œComp

Anavex (AVXL) reports Q1 GAAP EPS of -$0.14, beating estimates by $0.03, with $120.8M cash on hand ensuring a 4-year runway.

NEW YORK, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (”œAnavex” or the ”œCompany”) ( AVXL), a clinical-stage biopharmaceutical company

AVXL stock soars 95% in three months on positive updates from the development programs of its two clinical candidates, blarcamesine and ANAVEX 3-71.

Blarcamesine potential novel oral treatment to target upstream Alzheimer's disease pathology through autophagy enhancement Impairment of autophagy precedes bot

Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer's Disease

**media[513450]**

Anavex's promising Alzheimer's drug, Blarcamesine, could provide hope with its potential to slow cognitive decline, pending EMA approval. Read more here.

Anavex Life Sciences (AVXL) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Anavex Life Sciences Corp (AVXL), a clinical-stage biopharmaceutical company specializing in treatments for central nervous system (CNS) disorders, announced it

NEW YORK, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (”œAnavex” or the ”œCompany”) ( AVXL), a clinical-stage biopharmaceutical company

Here is how Anavex Life Sciences (AVXL) and AbbVie (ABBV) have performed compared to their sector so far this year.